Symbols / MESO Stock $14.51 -1.56% Mesoblast Limited

Healthcare • Biotechnology • Australia • NMS
MESO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Silviu Itescu FACP, FACRA, FRACP, MB…
Exch · Country NMS · Australia
Market Cap 1.88B
Enterprise Value 18.70B
Income -94.37M
Sales 65.38M
FCF (ttm) -69.44M
Book/sh 4.46
Cash/sh 0.10
Employees 81
Insider 10d —
IPO Jan 20, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -207.29
PEG —
P/S 28.69
P/B 3.25
P/C —
EV/EBITDA -290.67
EV/Sales 286.03
Quick Ratio 1.35
Current Ratio 1.58
Debt/Eq 23.52
LT Debt/Eq —
EPS (ttm) -0.69
EPS next Y -0.07
EPS Growth —
Revenue Growth 15.27%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-26
Earnings (prior) 2026-02-26
ROA -6.16%
ROE -18.22%
ROIC —
Gross Margin -35.53%
Oper. Margin -55.16%
Profit Margin -144.33%
Shs Outstand 129.28M
Shs Float 819.92M
Insider Own 5.05%
Instit Own 2.99%
Short Float 3.08%
Short Ratio 12.91
Short Interest 2.91M
52W High 21.50
vs 52W High -32.51%
52W Low 9.88
vs 52W Low 46.86%
Beta 0.79
Impl. Vol. 6.25%
Rel Volume 0.56
Avg Volume 248.85K
Volume 139.07K
Target (mean) $35.00
Tgt Median $35.00
Tgt Low $35.00
Tgt High $35.00
# Analysts 2
Recom Buy
Prev Close $14.74
Price $14.51
Change -1.56%
About

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$35.00
Mean price target
2. Current target
$14.51
Latest analyst target
3. DCF / Fair value
$-9.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.51
Low
$35.00
High
$35.00
Mean
$35.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-25 up Jefferies Hold → Buy —
2025-07-18 down Jefferies Buy → Hold —
2025-02-07 reit Piper Sandler Overweight → Overweight $24
2024-12-23 down Jefferies Buy → Hold —
2024-12-19 main Piper Sandler Overweight → Overweight $15
2024-07-23 up Piper Sandler Neutral → Overweight $11
2024-06-20 reit Cantor Fitzgerald — → Overweight —
2024-06-04 reit Cantor Fitzgerald — → Overweight —
News
RSS: Latest MESO news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
17.20
+191.39%
5.90
-21.32%
7.50
-26.54%
10.21
Operating Revenue
17.20
+191.39%
5.90
-21.32%
7.50
-26.54%
10.21
Cost Of Revenue
5.13
0.00
0.00
—
Reconciled Cost Of Revenue
5.13
0.00
0.00
—
Gross Profit
12.07
+104.47%
5.90
-21.32%
7.50
—
Operating Expense
74.51
+16.65%
63.87
-16.82%
76.79
-15.91%
91.32
Research And Development
34.81
-12.36%
39.72
-24.80%
52.82
+60.95%
32.81
Selling General And Administration
39.31
+57.36%
24.98
-9.10%
27.48
-52.59%
57.97
Selling And Marketing Expense
16.10
+36.58%
11.79
-15.43%
13.94
-54.68%
30.76
General And Administrative Expense
23.21
+75.93%
13.19
-2.58%
13.54
-50.24%
27.21
Salaries And Wages
18.73
+74.22%
10.75
+2.21%
10.52
+7.94%
9.75
Other Gand A
4.47
+83.47%
2.44
-19.24%
3.02
-88.90%
27.21
Other Operating Expenses
-0.09
+90.10%
-0.86
+75.50%
-3.51
-754.10%
0.54
Total Expenses
79.64
+24.68%
63.87
-16.82%
76.79
-15.91%
91.32
Operating Income
-62.44
-7.71%
-57.97
+16.33%
-69.29
+14.57%
-81.11
EBITDA
-80.06
-18.63%
-67.49
-7.71%
-62.66
+15.67%
-74.30
Normalized EBITDA
-59.69
-6.30%
-56.15
+17.98%
-68.46
+15.60%
-81.11
Reconciled Depreciation
6.40
+37.16%
4.67
+13.61%
4.11
-6.23%
4.38
EBIT
-80.06
-18.63%
-67.49
-7.71%
-62.66
+15.67%
-74.30
Total Unusual Items
-20.37
-79.62%
-11.34
-295.50%
5.80
-14.80%
6.81
Total Unusual Items Excluding Goodwill
-20.37
-79.62%
-11.34
-295.50%
5.80
-14.80%
6.81
Special Income Charges
-15.30
-27.06%
-12.04
-247.44%
8.17
+794.74%
0.91
Other Special Charges
0.42
-82.31%
2.35
+246.76%
0.68
+77.49%
0.38
Restructuring And Mergern Acquisition
14.89
+53.59%
9.69
+210.51%
-8.77
-860.68%
-0.91
Net Income
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Pretax Income
-101.81
-15.50%
-88.15
-7.36%
-82.10
+10.36%
-91.59
Net Non Operating Interest Income Expense
-19.00
-0.87%
-18.83
-1.19%
-18.61
-7.66%
-17.29
Interest Expense Non Operating
21.75
+5.30%
20.66
+6.24%
19.44
+12.47%
17.29
Net Interest Income
-19.00
-0.87%
-18.83
-1.19%
-18.61
-7.66%
-17.29
Interest Expense
21.75
+5.30%
20.66
+6.24%
19.44
+12.47%
17.29
Interest Income Non Operating
3.55
+94.85%
1.82
+119.49%
0.83
+27600.00%
0.00
Interest Income
3.55
+94.85%
1.82
+119.49%
0.83
+27600.00%
0.00
Other Income Expense
-20.37
-79.62%
-11.34
-295.50%
5.80
-14.80%
6.81
Gain On Sale Of Security
-5.07
-820.91%
0.70
+129.69%
-2.37
-140.16%
5.90
Tax Provision
0.33
+272.77%
-0.19
+9.91%
-0.21
+11.30%
-0.24
Tax Rate For Calcs
0.00
+13744.02%
0.00
-16.07%
0.00
-1.07%
0.00
Tax Effect Of Unusual Items
-6.11
-24768.89%
-0.02
-264.05%
0.01
-15.70%
0.02
Net Income Including Noncontrolling Interests
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Net Income From Continuing Operation Net Minority Interest
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Net Income From Continuing And Discontinued Operation
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Net Income Continuous Operations
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Normalized Income
-87.88
-14.67%
-76.64
+12.59%
-87.68
+10.66%
-98.14
Net Income Common Stockholders
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Diluted EPS
-0.85
+5.05%
-0.89
+15.38%
-1.05
+99.21%
-133.80
Basic EPS
-0.85
+5.05%
-0.89
+15.38%
-1.05
+99.21%
-133.80
Basic Average Shares
120.78
+22.41%
98.67
+26.87%
77.77
+13.89%
68.29
Diluted Average Shares
120.78
+22.41%
98.67
+26.87%
77.77
+13.89%
68.29
Diluted NI Availto Com Stockholders
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Gain On Sale Of PPE
0.00
0.00
-100.00%
0.08
0.00
Other Taxes
0.48
+1197.30%
0.04
0.00
-100.00%
0.00
Total Other Finance Cost
0.80
—
0.68
+77.49%
0.38
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
784.68
+17.27%
669.15
-0.04%
669.41
+1.10%
662.14
Current Assets
204.35
+136.34%
86.46
+5.88%
81.66
+16.93%
69.84
Cash Cash Equivalents And Short Term Investments
161.16
+157.59%
62.56
-11.78%
70.92
+18.13%
60.03
Cash And Cash Equivalents
161.16
+157.59%
62.56
-11.78%
70.92
+18.13%
60.03
Cash Equivalents
—
—
—
—
Cash Financial
161.16
+157.59%
62.56
-11.78%
70.92
+18.13%
60.03
Receivables
14.87
-29.05%
20.95
+199.40%
7.00
+58.94%
4.40
Accounts Receivable
13.91
+891.52%
1.40
-38.36%
2.28
+2.34%
2.22
Other Receivables
0.19
-98.94%
17.78
+9016.92%
0.20
—
Taxes Receivable
0.77
-56.24%
1.75
-61.23%
4.51
+106.93%
2.18
Accrued Interest Receivable
0.00
-91.30%
0.02
+27.78%
0.02
0.00
Inventory
22.25
0.00
—
—
Raw Materials
1.06
—
—
—
Work In Process
0.00
0.00
—
—
Finished Goods
21.18
0.00
—
—
Prepaid Assets
5.69
+122.93%
2.55
-23.67%
3.34
-32.99%
4.99
Restricted Cash
0.39
-1.01%
0.40
-0.25%
0.40
-3.63%
0.41
Total Non Current Assets
580.33
-0.40%
582.69
-0.86%
587.76
-0.77%
592.30
Net PPE
5.82
+51.72%
3.84
-40.87%
6.49
-34.86%
9.96
Gross PPE
23.99
-0.56%
24.13
-15.26%
28.47
+0.66%
28.29
Accumulated Depreciation
-18.17
+10.45%
-20.29
+7.69%
-21.98
-19.98%
-18.32
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
7.14
-21.80%
9.13
-8.33%
9.96
+0.00%
9.96
Machinery Furniture Equipment
9.65
+10.20%
8.76
-29.03%
12.34
+1.54%
12.15
Other Properties
7.21
+15.40%
6.25
+1.08%
6.18
+0.00%
6.18
Goodwill And Other Intangible Assets
571.83
-0.68%
575.74
-0.25%
577.18
-0.25%
578.65
Goodwill
134.45
+0.00%
134.45
+0.00%
134.45
+0.00%
134.45
Other Intangible Assets
437.37
-0.89%
441.28
-0.33%
442.73
-0.33%
444.20
Investments And Advances
1.39
+36.88%
1.01
-42.29%
1.76
-0.06%
1.76
Non Current Accounts Receivable
—
0.19
-54.11%
0.41
—
Non Current Prepaid Assets
0.25
+0.00%
0.25
+0.00%
0.25
+0.00%
0.25
Other Non Current Assets
0.47
-1.25%
0.48
+0.00%
0.48
-3.80%
0.50
Total Liabilities Net Minority Interest
187.24
-0.82%
188.80
+12.66%
167.58
+1.50%
165.10
Current Liabilities
102.63
+40.12%
73.24
+74.46%
41.98
-18.28%
51.37
Payables And Accrued Expenses
19.08
+169.90%
7.07
-64.90%
20.14
-12.71%
23.08
Payables
19.08
+169.90%
7.07
-64.90%
20.14
-12.71%
23.08
Accounts Payable
19.08
+169.90%
7.07
-64.90%
20.14
-12.71%
23.08
Employee Benefits
0.01
-42.31%
0.03
—
—
Pensionand Other Post Retirement Benefit Plans Current
6.23
-16.16%
7.44
—
—
Current Debt And Capital Lease Obligation
56.84
+244.71%
16.49
+64.68%
10.01
+22.05%
8.20
Current Debt
54.16
+290.67%
13.86
+132.90%
5.95
+18.64%
5.02
Other Current Borrowings
54.16
+290.67%
13.86
+132.90%
5.95
+18.64%
5.02
Current Capital Lease Obligation
2.68
+2.06%
2.63
-35.32%
4.06
+27.43%
3.19
Other Current Liabilities
16.73
-20.15%
20.95
+286.01%
5.43
+148.33%
2.19
Total Non Current Liabilities Net Minority Interest
84.61
-26.78%
115.56
-7.99%
125.59
+10.44%
113.72
Long Term Debt And Capital Lease Obligation
71.32
-30.37%
102.44
-3.80%
106.48
+7.88%
98.70
Long Term Debt
67.74
-32.59%
100.48
-2.26%
102.81
+12.22%
91.62
Long Term Capital Lease Obligation
3.58
+83.56%
1.95
-46.84%
3.67
-48.17%
7.08
Long Term Provisions
—
10.62
-36.07%
16.61
+32.65%
12.52
Non Current Deferred Liabilities
2.50
+0.00%
2.50
+0.00%
2.50
+0.00%
2.50
Non Current Deferred Taxes Liabilities
—
—
—
—
Other Non Current Liabilities
10.78
+1.74%
10.59
—
—
Stockholders Equity
597.44
+24.38%
480.36
-4.28%
501.84
+0.96%
497.04
Common Stock Equity
597.44
+24.38%
480.36
-4.28%
501.84
+0.96%
497.04
Capital Stock
1,508.85
+15.11%
1,310.81
+4.94%
1,249.12
+7.19%
1,165.31
Common Stock
1,508.85
+15.11%
1,310.81
+4.94%
1,249.12
+7.19%
1,165.31
Share Issued
1,279.97
+12.10%
1,141.78
+32.96%
858.73
+25.17%
686.03
Ordinary Shares Number
1,279.93
+12.15%
1,141.24
+32.99%
858.16
+25.20%
685.45
Treasury Shares Number
0.03
-94.03%
0.54
-5.19%
0.57
+0.00%
0.57
Retained Earnings
-1,010.90
-11.24%
-908.76
-10.72%
-820.80
-11.08%
-738.92
Gains Losses Not Affecting Retained Earnings
99.50
+27.07%
78.30
+6.51%
73.52
+4.06%
70.65
Total Equity Gross Minority Interest
597.44
+24.38%
480.36
-4.28%
501.84
+0.96%
497.04
Total Capitalization
665.18
+14.52%
580.84
-3.94%
604.65
+2.72%
588.66
Working Capital
101.72
+669.47%
13.22
-66.68%
39.68
+114.88%
18.46
Invested Capital
719.34
+20.96%
594.70
-2.60%
610.60
+2.85%
593.68
Total Debt
128.16
+7.76%
118.92
+2.08%
116.50
+8.97%
106.91
Net Debt
—
51.78
+36.83%
37.84
+3.40%
36.60
Capital Lease Obligations
6.26
+36.81%
4.58
-40.79%
7.73
-24.72%
10.27
Net Tangible Assets
25.62
+126.86%
-95.38
-26.59%
-75.34
+7.67%
-81.61
Tangible Book Value
25.62
+126.86%
-95.38
-26.59%
-75.34
+7.67%
-81.61
Available For Sale Securities
1.39
+36.88%
1.01
-42.29%
1.76
-0.06%
1.76
Current Provisions
3.75
-82.40%
21.30
+232.93%
6.40
-64.26%
17.91
Investmentin Financial Assets
1.39
+36.88%
1.01
-42.29%
1.76
-0.06%
1.76
Non Current Note Receivables
0.57
-51.74%
1.18
+0.00%
1.18
+0.08%
1.18
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-49.95
-3.09%
-48.46
+23.41%
-63.27
+3.82%
-65.78
Cash Flow From Continuing Operating Activities
-49.95
-3.09%
-48.46
+23.41%
-63.27
+3.82%
-65.78
Net Income From Continuing Operations
-102.14
-16.13%
-87.96
-7.41%
-81.89
+10.35%
-91.35
Depreciation Amortization Depletion
6.40
+37.16%
4.67
+13.61%
4.11
-6.23%
4.38
Depreciation And Amortization
6.40
+37.16%
4.67
+13.61%
4.11
-6.23%
4.38
Other Non Cash Items
21.43
-34.04%
32.48
+186.19%
11.35
-30.68%
16.38
Stock Based Compensation
22.09
+276.29%
5.87
+60.60%
3.65
-33.98%
5.54
Deferred Tax
0.33
+272.77%
-0.19
+9.91%
-0.21
+9.79%
-0.23
Deferred Income Tax
0.33
+272.77%
-0.19
+9.91%
-0.21
+9.79%
-0.23
Operating Gains Losses
4.99
+811.13%
-0.70
-131.99%
2.19
+140.88%
-5.36
Gain Loss On Investment Securities
4.96
+736.97%
-0.78
-135.33%
2.21
+137.40%
-5.90
Net Foreign Currency Exchange Gain Loss
0.02
-70.51%
0.08
+25.81%
0.06
-88.43%
0.54
Gain Loss On Sale Of PPE
0.00
0.00
+100.00%
-0.08
0.00
Change In Working Capital
-3.04
-15.62%
-2.63
-6.43%
-2.47
-150.77%
4.87
Change In Receivables
6.29
+145.00%
-13.98
-457.70%
-2.51
-1890.00%
0.14
Changes In Account Receivables
5.02
+132.46%
-15.47
-13006.78%
-0.12
-184.29%
0.14
Change In Inventory
0.83
0.00
0.00
—
Change In Prepaid Assets
-3.02
-473.98%
0.81
-51.09%
1.65
+6.11%
1.55
Change In Payables And Accrued Expense
11.78
+195.17%
-12.38
-3010.05%
-0.40
-108.33%
4.78
Change In Payable
11.78
+195.17%
-12.38
-3010.05%
-0.40
-108.33%
4.78
Change In Other Working Capital
-18.92
-182.56%
22.92
+1981.44%
-1.22
+24.02%
-1.60
Change In Other Current Assets
—
—
—
—
Investing Cash Flow
0.12
+223.71%
-0.10
+50.00%
-0.19
+16.38%
-0.23
Cash Flow From Continuing Investing Activities
0.12
+223.71%
-0.10
+50.00%
-0.19
+16.38%
-0.23
Net PPE Purchase And Sale
-0.68
-150.92%
-0.27
-2.65%
-0.26
-68.15%
-0.16
Purchase Of PPE
-0.68
-150.92%
-0.27
-2.65%
-0.26
-68.15%
-0.16
Capital Expenditure
-0.73
-120.54%
-0.33
-5.41%
-0.31
-35.34%
-0.23
Net Investment Purchase And Sale
0.24
+2.99%
0.23
+95.00%
0.12
0.00
Sale Of Investment
0.24
+2.99%
0.23
+95.00%
0.12
0.00
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
-0.05
+16.67%
-0.06
-20.00%
-0.05
+33.33%
-0.07
Purchase Of Intangibles
-0.05
+16.67%
-0.06
-20.00%
-0.05
+33.33%
-0.07
Net Other Investing Changes
0.61
—
0.12
—
Financing Cash Flow
147.34
+266.03%
40.25
-45.97%
74.50
+854.83%
-9.87
Cash Flow From Continuing Financing Activities
147.34
+266.03%
40.25
-45.97%
74.50
+854.83%
-9.87
Net Issuance Payments Of Debt
-9.77
+27.78%
-13.52
-409.11%
-2.66
+58.02%
-6.33
Issuance Of Debt
—
0.00
0.00
-100.00%
51.92
Repayment Of Debt
-9.77
+27.78%
-13.52
-409.11%
-2.66
+95.44%
-58.25
Long Term Debt Issuance
—
0.00
0.00
-100.00%
51.92
Long Term Debt Payments
-9.77
+27.78%
-13.52
-409.11%
-2.66
+95.44%
-58.25
Net Long Term Debt Issuance
-9.77
+27.78%
-13.52
-409.11%
-2.66
+58.02%
-6.33
Net Common Stock Issuance
161.21
+146.47%
65.41
-26.21%
88.64
+42309.09%
0.21
Cash Dividends Paid
0.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
6.82
0.00
0.00
-100.00%
8.08
Net Other Financing Charges
-5.66
+4.28%
-5.92
-8.27%
-5.46
+4.97%
-5.75
Changes In Cash
97.50
+1274.30%
-8.30
-175.22%
11.04
+114.55%
-75.88
Effect Of Exchange Rate Changes
1.09
+2080.00%
-0.06
+67.26%
-0.17
+69.45%
-0.55
Beginning Cash Position
62.96
-11.72%
71.32
+17.98%
60.45
-55.84%
136.88
End Cash Position
161.55
+156.59%
62.96
-11.72%
71.32
+17.98%
60.45
Free Cash Flow
-50.68
-3.88%
-48.79
+23.27%
-63.58
+3.68%
-66.01
Cash Flowsfromusedin Operating Activities Direct
-49.95
-3.09%
-48.46
+23.41%
-63.27
+3.82%
-65.78
Classesof Cash Payments
-60.11
+1.19%
-60.84
+16.30%
-72.68
+4.10%
-75.79
Classesof Cash Receiptsfrom Operating Activities
6.61
-37.65%
10.60
+22.99%
8.62
-13.85%
10.00
Common Stock Issuance
161.21
+146.47%
65.41
-26.21%
88.64
+42309.09%
0.21
Interest Paid CFF
-5.27
+7.89%
-5.72
+4.94%
-6.01
+1.15%
-6.08
Interest Paid Direct
—
—
—
—
Interest Received Direct
3.55
+99.61%
1.78
+123.37%
0.80
+11271.43%
0.01
Issuance Of Capital Stock
161.21
+146.47%
65.41
-26.21%
88.64
+42309.09%
0.21
Other Cash Receiptsfrom Operating Activities
0.91
-76.30%
3.82
+241.59%
1.12
+4558.33%
0.02
Paymentsto Suppliersfor Goodsand Services
-60.11
+1.19%
-60.84
+16.30%
-72.68
+4.07%
-75.77
Receiptsfrom Customers
5.70
-15.82%
6.78
-9.41%
7.48
-25.05%
9.98
Receiptsfrom Government Grants
—
—
—
0.02
Taxes Refund Paid Direct
-0.00
-150.00%
0.00
-80.00%
0.02
+183.33%
-0.02
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category